Full text is available at the source.
Abstract
The prevalence of glucagon-like peptide-1 (GLP-1) use before total joint arthroplasty (TJA) was assessed.
- Weight loss in patients using GLP-1s was measured.
- The association of GLP-1 use with patient outcomes after TJA was evaluated.
- Findings may provide insights into the role of GLP-1s in managing patients prior to surgery.
Simplified